Page last updated: 2024-08-21

pyrazines and etp-46321

pyrazines has been researched along with etp-46321 in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aguirre, E; Albarrán, M; Alfonso, P; Barbacid, M; Bischoff, JR; Cebrián, D; Cendón, E; Fominaya, J; García-Serelde, B; Gomez-Casero, E; Gonzalez-Granda, T; Hernández, AI; Link, W; Lorenzo, M; Martín, JI; Martínez González, S; Mulero, F; Oyarzabal, J; Pastor, J; Pizcueta, P; Rabal, O; Ramos-Lima, F; Rivero, V; Rodríguez, A; Rodríguez-Arístegui, S; Saluste, CG; Varela, C1
Albarran, MI; Alonso, P; Anguita, PV; Bischoff, JR; Cebriá, A; Cebrián, D; Fominaya, J; Granda, TG; Link, W; López, AR; López, EC; Lorenzo, M; Martínez, S; Merino, T; Palacios, I; Pastor, J; Peregrina, S; Serelde, BG1
Acosta, YY; Aragoneses-Fenoll, L; Blanco-Aparicio, C; Criado, G; Dianzani, U; Herranz, J; Martínez, S; Montes-Casado, M; Ojeda, G; Pastor, J; Portolés, P; Rojo, JM1
Albarrán, MI; Alfonso, P; Álvarez, RM; Bischoff, JR; Cebriá, A; Cebrián, D; Cendón, E; González Cantalapiedra, E; Hernández, AI; Martínez González, S; Pastor, J; Rodríguez Hergueta, A; Rodríguez-Arístegui, S; Varela, C1
Albarrán, MI; Álvarez, RM; Bischoff, JR; Blanco-Aparicio, C; Cebriá, A; Cebrián, D; García-Arocha, J; Hernández, AI; Hernández-Encinas, E; Martínez González, S; Pastor, J; Ramos-Lima, F; Rodríguez, A1

Other Studies

5 other study(ies) available for pyrazines and etp-46321

ArticleYear
Identification of ETP-46321, a potent and orally bioavailable PI3K α, δ inhibitor.
    Bioorganic & medicinal chemistry letters, 2012, May-15, Volume: 22, Issue:10

    Topics: Administration, Oral; Biological Availability; Humans; Imidazoles; Isoenzymes; Phosphoinositide-3 Kinase Inhibitors; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrazines; Tomography, X-Ray Computed

2012
Biological characterization of ETP-46321 a selective and efficacious inhibitor of phosphoinositide-3-kinases.
    Investigational new drugs, 2013, Volume: 31, Issue:1

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; Female; Humans; Imidazoles; Mice; Mice, Inbred BALB C; Mice, SCID; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pyrazines; Xenograft Model Antitumor Assays

2013
ETP-46321, a dual p110α/δ class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis.
    Biochemical pharmacology, 2016, Apr-15, Volume: 106

    Topics: Animals; Antibodies; Arthritis, Experimental; CD28 Antigens; CD3 Complex; CD4-Positive T-Lymphocytes; Class Ia Phosphatidylinositol 3-Kinase; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Gene Expression; Imidazoles; Interferon-gamma; Interleukin-10; Interleukin-2; Lymph Nodes; Lymphocyte Activation; Mice; Mice, Inbred C57BL; NFATC Transcription Factors; Phosphoinositide-3 Kinase Inhibitors; Protein Subunits; Proto-Oncogene Proteins c-akt; Pyrazines; T-Box Domain Proteins

2016
Generation of tricyclic imidazo[1,2-a]pyrazines as novel PI3K inhibitors by application of a conformational restriction strategy.
    Bioorganic & medicinal chemistry letters, 2017, 06-01, Volume: 27, Issue:11

    Topics: Animals; Half-Life; Humans; Imidazoles; Inhibitory Concentration 50; Mice; Microsomes, Liver; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Isoforms; Protein Kinase Inhibitors; Pyrazines; Structure-Activity Relationship

2017
Identification of novel PI3K inhibitors through a scaffold hopping strategy.
    Bioorganic & medicinal chemistry letters, 2017, 11-01, Volume: 27, Issue:21

    Topics: Administration, Oral; Animals; Chemistry, Pharmaceutical; Drug Evaluation, Preclinical; Half-Life; Imidazoles; Inhibitory Concentration 50; Mice; Mice, Inbred BALB C; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Isoforms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; TOR Serine-Threonine Kinases

2017